Risk monitoring

Teaches how to obtain and maintain valid informed consent through clear disclosure, comprehension checks, capacity support, voluntariness, non-coercion, and respect for refusal or withdrawal. The competency also covers consent for screening procedures, recordings, collateral contact, rescue interventions, and documentation of the consent process.

Cluster covering 31 related competencies including: Integration support, Integration therapy, Integration coaching.

Teaches protection of participant identity, sensitive clinical or occupational information, recordings, and research data. The competency covers coded identifiers, restricted access, secure handling, confidentiality safeguards, and privacy-preserving documentation.

Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.

Teaches how to detect, elicit, document, and report adverse events and serious adverse events across the participant journey. The focus is accurate source documentation, regulatory reporting discipline, follow-up, and preservation of participant safety and trial integrity.

Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.

Teaches how to assess clinical suitability before psychedelic or ketamine treatment, including medical and psychiatric screening, readiness evaluation, contraindication review, inclusion/exclusion criteria, and ongoing eligibility re-checks before dosing.

Teaches faithful delivery of manualized treatment and protocol-defined procedures while documenting and managing unavoidable deviations. The competency protects participant welfare, treatment consistency, data integrity, and sponsor oversight.

Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.

Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.

Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.

Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.

Teaches delivery of psychedelic-assisted psychotherapy according to an approved study manual across preparation, dosing, integration, and follow-up. The competency balances standardized structure with non-directive support for the participant’s therapeutic process.

Teaches accurate study documentation, source-record quality, secure data capture, Good Clinical Practice recordkeeping, IRB and sponsor documentation requirements, monitoring readiness, audit support, accountability, and retention obligations.

Teaches how to preserve blinded trial conduct across participant interactions, outcome collection, staff roles, and session procedures. The competency includes preventing accidental unblinding, minimizing bias, and using emergency unblinding only when clinically necessary.

Teaches coordinated practice across co-therapists, physicians, psychiatrists, study coordinators, principal investigators, and other care-team members. The focus is shared responsibility, clear communication, role clarity, and coordinated observation of participant status.

Teaches adherence to Good Clinical Practice, assigned study roles, protocol procedures, delegation boundaries, and applicable research regulations. The competency supports consistent execution of approved procedures across sites and participants.

Teaches how to understand ClinicalTrials.gov records and related study information, including glossary terms, registration fields, protocol descriptors, and results-reporting elements used to interpret clinical research records.

Cluster covering 2 related competencies including: Therapeutic alliance building, Therapeutic alliance and rapport building.

Teaches how to maintain clear relational and physical boundaries in emotionally vulnerable treatment settings. This includes professional conduct, rapport without overreach, explicit consent for touch, the right to revoke consent, and strict prohibition of sexual or erotic contact.

Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.

Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.

Provides supportive therapeutic presence while the patient is under the influence of ketamine. Uses calming, noncoercive guidance to help the patient navigate dissociation and emotional material.

Cluster covering 11 related competencies including: Preparation support, Psilocybin preparation, Therapeutic preparation.

Teaches structured pre-dose preparation and post-dose integration as the therapeutic frame for psychedelic-assisted psychotherapy. The therapist supports rapport, intention clarification, meaning-making, emotional processing, and consolidation of insights after dosing.

Able to practice ethically in a clinical trial environment involving a Schedule-sensitive psychoactive intervention. This includes protecting participants, adhering to protocol, and supporting valid informed participation.

Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.

Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.

Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.

Cluster covering 6 related competencies including: Therapeutic support during dosing, Nondirective dosing-session presence, Supportive dosing-session facilitation.

Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.

Cluster covering 9 related competencies including: Psilocybin facilitation, Psilocybin session support, Psilocybin facilitation basics.

Therapists must facilitate rather than control the participant's process, using invitations and timing interventions carefully. They should preserve the participant-led unfolding of experience while knowing when gentle direction or safety-based assertiveness is needed.

Teaches practices that support preparation and therapeutic presence, including mindfulness, intention-setting, body-aware attention, environmental preparation, mindset awareness, and regulation through somatic presence.

Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.

The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.

Cluster covering 12 related competencies including: KAP psychotherapy delivery, Ketamine and KAP knowledge, Ketamine integration planning.

Teaches structured monitoring of depressive symptoms, response, and remission across treatment and follow-up. Learners use standardized scales and clinical review to track change and identify deterioration or non-response.

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

Clinicians and research staff must clearly educate participants about study procedures, risks, side effects, restrictions, and possible benefits, and obtain written informed consent before screening and study participation. Ethical delivery depends on transparent communication and opportunities for questions.

Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.

Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.

Teaches how to instruct participants on post-dose and study-period restrictions that reduce risk from impaired judgment, unsafe activity, prohibited substances, or behaviors that could confound study outcomes.

Cluster covering 2 related competencies including: Psychedelic-assisted therapy facilitation, Group facilitation in a psychedelic setting.

Teaches culturally responsive psychedelic care, including humility, anti-bias practice, Indigenous and traditional-use awareness, cultural appropriation concerns, diversity and inclusion, and respectful work with marginalized communities.

Therapists must be able to teach and coach grounding practices that help participants regulate during preparation and dosing. These methods are used before medication and during distress.

Teaches clinicians and research staff to understand the purpose, limits, scoring, interpretation, and clinical meaning of psychological measures and study instruments used to evaluate symptoms, functioning, safety, and treatment outcomes.

Understand the pharmacology and interaction risks of 5-MeO-DMT/BPL-003, including serotonergic and cardiovascular concerns. This knowledge informs safe preparation, exclusion screening, and monitoring.

Teaches a trauma-informed stance during psychedelic work, including calm presence, non-verbal reassurance, body-aware support, somatic orientation, and containment through difficult experiences while maintaining safety and boundaries.

The study used standardized anxiety measures and followed patients for 2 months and 12 months, implying competence in tracking outcomes over time. Therapists should be able to assess symptom change and sustained benefit using structured follow-up.

Maintain a contained therapeutic environment that protects the patient’s privacy and minimizes unwanted exposure. The session structure emphasizes confidentiality and controlled access to stimulation and outside contact.

Cluster covering 2 related competencies including: Medical escalation and rescue medication use, Medical escalation and rescue medication coordination.

Cluster covering 4 related competencies including: Therapeutic rapport building, Rapport building and trust development, Therapeutic rapport and trust building.

Teaches structured clinical interviewing and assessment administration for PTSD and related symptom domains, including symptom severity, functional impairment, risk factors, and appropriate use of standardized assessment tools.

Therapists must help patients face and work through grief, fear, rage, panic, shame, guilt, and existential distress rather than avoid them. The clinician supports emotional expression while maintaining safety and meaning-making.

Support decision-making about ongoing treatment after trial completion, particularly for participants who received escitalopram. The clinician helps participants consider whether to continue, taper, or return to usual care.

Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.

Facilitate trauma exposure in a structured, supportive, and protocol-consistent manner. The therapist must be able to initiate, pace, and process exposure work while maintaining adherence to PE methods.

Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.

Cluster covering 4 related competencies including: Psychedelic therapy workflow, Psilocybin psychotherapy framework, Psilocybin-assisted psychotherapy framework.

Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.

Teaches providers to create and maintain a psychologically and physically safe therapeutic setting through clear structure, preparation, boundaries, attunement, environmental design, and ongoing attention to participant safety.

Ability to administer and interpret structured interviews, clinician ratings, and self-report measures used in the study. Therapists contribute to eligibility, safety, and outcome assessment.

Therapists and study clinicians perform detailed biopsychosocial interviewing during preparation and screening. This supports treatment planning, risk assessment, and therapeutic understanding.

Facilitators must be able to contain and support intense psychological distress during the session. The study notes that the experience could be emotionally difficult even when participants felt safe.

Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.

Prepare participants for the dosing session and guide them through standardized procedures. The facilitator should ensure readiness, adherence to study rules, and smooth progression through the session schedule.

Therapists must ensure continuity of care after the acute session, including overnight observation and next-morning integration before discharge. This reflects a containment and recovery responsibility beyond the dosing period.

Therapists/facilitators must know the psychiatric and medical conditions that make KPT unsafe or inappropriate. Safe practice depends on excluding high-risk individuals.

Knows when to involve physicians, psychologists, and independent safety oversight. Complex psychedelic sessions require clear escalation pathways and team coordination.

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

Cluster covering 2 related competencies including: Preparation of set and setting, Client preparation and therapeutic set/setting.

The training includes appropriate use of therapeutic touch as part of safe delivery. Learners are expected to use touch judiciously and within ethical boundaries.

The framework implies competence in evaluating both symptom change and subjective outcomes over time. The study used standardized anxiety measures and qualitative interviews to assess sustained effects and patient-reported change.

Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.

Therapists should accurately represent the current evidence base and avoid overstating efficacy or durability. The article notes significant short-term benefit but also the need for larger multicenter trials and longer follow-up.

Understand the characteristic acute experiential domains elicited by ayahuasca. This includes perceptual, somatic, cognitive, affective, mystical, and temporal-spatial alterations.

Administer and interpret psychological and psychometric measures relevant to mood, cravings, expectations, mystical experience, ego dissolution, and functioning. Facilitators must accurately support questionnaire-based assessment across time points.

Therapists and facilitators should communicate treatment effects responsibly and acknowledge methodological limitations. The paper notes small sample size, lack of long-term control group, and need for further study of mechanisms.

The use of ayahuasca requires sensitivity to its traditional indigenous and ceremonial origins. Facilitators should avoid reducing the practice to a purely technical intervention and should respect cultural meaning and ceremonial context.

Provide a calm and supportive environment during treatment to reduce distress and support tolerance of the experience. The case report notes food, rest, and a quiet place as part of care.

Create an environment that supports safety, comfort, and relaxation during the session. The setting is deliberately structured to reduce anxiety and facilitate a positive experience.

Ability to evaluate alcohol and other substance use patterns using standardized tools and clinical interview. This is essential for eligibility, safety, and outcome monitoring.

Therapists and study personnel are expected to receive structured training and ongoing supervision. Competence includes both protocol adherence and the ability to work safely and consistently across sites.

Teaches recognition and management of relational dynamics that can intensify in psychedelic-assisted therapy. Learners develop self-awareness around countertransference, projection, attachment, dependency, and other therapeutic-process risks.

Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.

Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.

The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.

Where co-therapy is used, therapists should work cohesively, remain present, and respect participant preferences within the dyad.

The therapist is responsible for giving truthful, individualized preparation and reassurance about the experience, including likely sensations, risks of resistance, and expectations for conduct. The preparation aims to reduce fear, improve cooperation, and support voluntary participation.

Cluster covering 4 related competencies including: Integration and debriefing, Integration and debriefing facilitation, Integration and post-session debriefing.

Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.

Uses motivational interviewing methods to strengthen intrinsic motivation and commitment to change. Tailors discussions to the participant’s ambivalence, goals, and readiness to change drinking behavior.

Facilitators must balance active safety monitoring with minimal interference in the participant’s inner experience. The role includes maintaining continuous presence, periodic check-ins, and preserving the therapeutic container of the session.

Conduct preparatory sessions that orient the subject, assess readiness, and set expectations for MDMA-assisted psychotherapy. These sessions are used to prepare for safety, adherence, and therapeutic engagement.

Participant safety and wellbeing must take precedence over scientific objectives at all times. Therapists must communicate and operationalize this priority throughout screening, treatment, and follow-up.

Therapists may record sessions only with explicit participant consent and must handle recordings for training and research within protocol limits. Recording is part of the therapeutic and scientific framework, not routine clinical use.

Administer study measures and structured assessments on schedule, including psychological, spiritual, and neurobehavioral instruments. This includes both paper-based and Storyline-based assessments.

Ability to provide a consistent, supportive therapeutic environment during intensive psychedelic-assisted sessions. The facilitation role depends on maintaining trust and emotional safety.

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

Understands that MDMA is a Schedule 1 investigational product and must be stored, dispensed, and accounted for under regulatory control. Supports compliant handling during the session.

Therapists are expected to provide consistent empathic presence, nonjudgmental attunement, and deep listening throughout the process. This includes validating feelings, listening for deeper meaning, and creating psychological permission for openness.

Therapists/facilitators should be able to judge whether therapeutic change reaches clinically meaningful thresholds, not just whether symptoms improve numerically. This supports informed ongoing care and communication about benefits and limitations.

Cluster covering 5 related competencies including: Cardiac safety monitoring, Ketamine infusion monitoring, Ketamine infusion administration.

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

Therapists must be able to elicit a full account of the dosing experience without overinterpreting it. The goal is to help participants remember, narrate, and reflect on their experience in detail.

Can identify and involve support persons, attendants, and outside providers to enhance safety. The facilitator must coordinate practical supports while respecting confidentiality and protocol boundaries.

Cluster covering 2 related competencies including: Psilocybin psychoeducation, Psychedelic psychoeducation and expectation management.

Therapists should support evaluation, emotional processing, and integration after the acute experience. This includes helping patients reflect without over-directing or interrupting the process.

Possess sufficient knowledge of chronic treatment-resistant PTSD to support subject selection, psychotherapy, and symptom monitoring. The protocol situates the intervention within established PTSD symptom and treatment frameworks.

Adapt language and interpersonal style to the patient’s preferences to promote dignity and comfort. The therapist should also respect the patient’s autonomy within safety limits.

The therapist must create an atmosphere of confidence and mutual understanding before ketamine administration. This relationship is treated as a key therapeutic factor in the protocol.

Therapists should communicate in language and nonverbal style the participant can readily follow, avoiding overly theoretical or confusing discourse.

Cluster covering 2 related competencies including: Session facilitation and therapeutic holding, Session facilitation and support during intense experiences.

The protocol implies that facilitators should have specific psychiatric, psychotherapeutic, or psycholytic therapy training relevant to altered-state treatment. Specialized experience supports safe and effective delivery of LSD-assisted psychotherapy.

Understand how treatment expectations can influence treatment response and study interpretation. Facilitation must avoid inadvertently shaping expectations in a biased or misleading way.

Accept the patient’s experience as meaningful without disputing or forcing interpretation. The therapist supports reflection while avoiding premature conclusions about reality or correctness.

Facilitators are responsible for ensuring that participants have provided informed consent before receiving MDMA-assisted therapy. This reflects an ethical and regulatory duty central to work with investigational treatments.

Understand the clinical and neurobehavioral rationale for PE and exposure-based treatment. The therapist should know how extinction learning is conceptualized in the study model.

Therapists must protect voluntariness when potential participants are also their patients. Independent evaluation should be used to reduce pressure or perceived coercion in recruitment and consent.

Therapists/facilitators need judgment about dosing and setting so experiences remain tolerable and therapeutically useful. The paper repeatedly notes that when dose and setting are appropriate, emerging material remains within the patient’s capacity to cope.

Study clinicians are responsible for administering study drug, ensuring correct dose assignment, and supervising safe oral ingestion during blinded sessions. This includes verifying visit-specific randomization information and ensuring dosing is delivered under the blinded workflow.

Lead therapists must hold appropriate licensure and regulatory registration to provide psychotherapy, and have prior PAP experience. Unlicensed or inexperienced therapists may participate only under direct supervision.

Coordinate effectively with the study clinician, medical monitor, rater team, and MRI staff. Facilitation is embedded in a broader clinical-research workflow requiring timely communication.

Understands and applies the protocol-defined criteria for treatment-resistant major depressive disorder, including diagnostic confirmation, episode severity, and prior treatment failure requirements. Must verify both current and historical antidepressant nonresponse and ensure the participant remains eligible at baseline.

Know the sequence, timing, and purpose of screening, preparation, dosing, scanning, follow-up, and unblinding visits. The therapist/facilitator must be able to work within the full protocol structure.

Capacity to conduct assessments and therapy sessions virtually when needed while preserving safety and confidentiality. The study permits telehealth sessions for certain visits and contingencies.

Teaches sustainable self-care practices for clinicians and facilitators working in emotionally intense settings. The competency supports emotional resilience, ethical boundaries, reflective practice, and burnout prevention.

Teaches clinicians to recognise their role boundaries, align services with training, licensure, supervision, and organisational policy, and refer or escalate when participant needs fall outside their scope of competence.

The program includes facilitator development and self-care, and it explicitly calls on learners to recognize personal limitations and seek support. This suggests training in reflective practice and professional self-management.

The course explicitly mentions the role of music and therapist variables in treatment. Learners are expected to understand how these elements influence the PAP experience and therapeutic outcome.

The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.

Facilitator must understand opioid use disorder, medication-assisted treatment, and the clinical rationale for adjunctive psychotherapy. The protocol frames MORE+KAP as an investigational augmentation to buprenorphine treatment.

Therapists should support an appropriate rhythm between inward experiential focus and verbal interaction, with either therapist or participant able to initiate shifts.

Engages in ongoing supervision and accepts feedback to maintain treatment quality. Supports corrective action when performance is unsatisfactory.

The intervention involved two separate psilocybin dosing sessions 3 weeks apart under a randomized controlled protocol, implying the need for facilitators to reliably support treatment according to a fixed schedule and study procedures.

Competence in delivering online psychotherapy through secure platforms consistent with privacy requirements. The protocol specifies secure videoconferencing in compliance with HIPAA guidelines.

Document participant experiences and relevant observations to support continuity, recall, and study integrity. Notes may also serve as a participant memory aid after dosing sessions.

Competent facilitation requires practical knowledge of dosage ranges, initial dosing, boosters, formulation handling, and administration errors. The handbook stresses both clinical judgment and meticulous procedural care.

Therapists must listen with nonjudgmental, emotionally attuned presence and convey validation, reassurance, and curiosity. They should be able to stay relaxed yet engaged, including noticing nonverbal cues and responding without prying.

After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.

Therapists/facilitators must support ethically valid informed consent by ensuring participants understand the intervention, expectations, risks, and logistics. They also provide anticipatory guidance before ketamine sessions and discharge information after dosing.

Combined ketamine infusion and PE treatment requires coordination between psychotherapy providers and medical/anesthesia or medication administration staff. Effective collaboration supports timing, safety oversight, and protocol fidelity.

Reviews laboratory and ECG data for clinically relevant abnormalities and determines whether continued participation is appropriate. Escalates abnormalities requiring repeat testing or specialist input.

Because the paper notes limited conclusions about efficacy due to the crossover design, clinicians have an ethical responsibility to avoid overstating treatment effects. Competence includes accurately presenting the evidence base, uncertainty, and limits of inference to patients and colleagues.

Respond to agitation or attempts to leave the room in a way that preserves safety for the patient and others. The therapist should use containment, redirection, and escalation protocols when needed.

Therapists must prepare the subject for residual effects after the main session and provide practical safeguards for sleep, transportation, and home support. This includes framing recurrence of symptoms in a non-alarming way.

The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

The facilitator must ensure non-responders are transitioned safely back to clinical care. Continuity of care is explicitly required to support ongoing psychiatric treatment.

Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.

Teaches clear communication of behavioral requirements before dosing sessions so conditions are standardized and preventable risks are reduced. Staff confirm that participants understand and follow pre-session instructions.

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

Follows the study's operational rules for dose timing, progression, and stopping conditions. Reliable execution is necessary for both safety and interpretability of results.

Facilitators must know the risks and contraindications associated with ayahuasca use. They should identify medical and psychological factors that make participation unsafe or require extra caution.

Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.

Tailor therapeutic engagement to patients with advanced non-operable GI cancers facing existential distress, grief, and limited life expectancy. The therapist/facilitator must recognize the emotional and medical context of end-of-life suffering.

At least one therapist must be able to teach stress inoculation methods, especially diaphragmatic breathing, and apply breath-based interventions during sessions. Breath is used both for relaxation and for staying present with difficult experience.

Facilitators must competently administer and interpret clinician-rated ADHD and global severity measures. Accurate scoring is essential because these scales determine eligibility and outcomes.

Although formal measurements may be conducted by another researcher, therapists/facilitators must work within a protocol that includes repeated anxiety assessments and daily diaries of anxiety, pain, and medication use. This implies competence in reinforcing adherence to monitoring procedures and integrating findings into care awareness.

Therapists must be able to help participants confront, tolerate, and work through intense experiences rather than prematurely suppress them. The method emphasizes support, reassurance, emotional processing, and integration of meaningful material.

Therapists should orient to and explore the participant’s somatic experience, both in experimental and integrative sessions, as a central channel of processing.

Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.

Helps participants convert motivation into specific behavior-change strategies. Uses structured planning tools and individualized modules to address triggers, coping, and alternative behaviors.

Have a working understanding of moderate to severe AUD, relapse processes, craving, withdrawal, and common comorbidities. This knowledge is required to deliver the integrated treatment model safely and effectively.

Therapists should understand the participant’s support network and appropriately involve support persons when relevant and desired.

Uses assessment findings to individualize therapy and medication-session preparation. Adapts the approach based on participant response, goals, and clinical presentation.

Therapists must ensure attendants are appropriately selected and instructed for overnight monitoring. Attendants provide supportive care and observation without taking on psychotherapeutic functions.

Understand the proposed mechanisms, phases of effect, and common subjective and physical effects of ibogaine relevant to clinical supervision. This knowledge informs safe monitoring and therapeutic pacing.

Collect smoking-related behavioral data and participant-reported outcomes repeatedly across the trial. Facilitators must accurately gather self-report, breath CO, urine, and questionnaire data according to protocol.

Teaches the use of independent or blinded assessors to reduce expectancy and observer bias, preserve separation between therapeutic and rating roles, manage unblinding risks, and protect outcome validity in open-label or partially blinded designs.

Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

Therapists must practice within the population and setting defined by the manual, limiting use to approved clinical trial subjects with PTSD. This boundary helps protect participants and preserves research integrity.

Ability to monitor for short-term cognitive impairment following psychedelic administration. The study included tests designed to detect decrements in attention and processing speed.

Therapists function within a medically supervised ketamine model and must coordinate closely with clinicians responsible for dosing oversight and safety clearance. This includes understanding role boundaries and supporting monitoring workflows.

Can safely administer vaporized GH001 using standardized equipment and procedure. Accurate delivery and participant instruction are essential to reliable dosing.

Therapists must coordinate with prescribing clinicians and existing psychotherapists when relevant, while respecting consent and confidentiality. Communication should support safety, continuity, and protocol integrity.

Therapists and facilitators must be able to guide intentional group process in a way that supports safety, connection, and meaningful change. This includes managing both large- and small-group formats and maintaining a relationally anchored therapeutic environment.

Work within an approved research framework that has institutional review board authorization. Ethical practice requires adherence to the approved study protocol and oversight requirements.

Facilitators need to understand the full treatment sequence and how each phase contributes to safety and treatment delivery. The intervention depends on correct sequencing and timing.

Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

Safety monitoring in this context includes tracking not only adverse psychiatric states but also broader psychological, emotional, existential, and spiritual outcomes. Clinicians should watch for changes across multiple domains that may affect patient functioning and care needs.

Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.

When overnight stays are required, facilitators and attendants must maintain safe observation and supportive presence without acting as outside therapists. They need to monitor comfort, safety, and emergency access overnight.

Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.

Ability to observe and respond to participants during MDMA medicine sessions, including both psychological experience and physiological change. The protocol indicates an interest in psychological and physiological processes of change during treatment.

The protocol explicitly addresses the risk of undue influence when investigators recruit current or former patients, requiring safeguards and ongoing monitoring for coercion.

Ability to manage the study schedule, windows, and follow-up procedures accurately. This supports treatment delivery and valid outcome collection.

Therapists must understand MDMA’s expected subjective, interpersonal, and physiological effects and prepare participants accordingly. This knowledge supports normalization, reassurance, and effective use of the medicine within therapy.

Deliver ongoing relapse prevention psychotherapy after dosing through the post-dose follow-up period. The approach is used to support alcohol recovery and translate treatment effects into behavior change.

Ability to administer standardized clinical ratings consistently and under supervision. Reliable measurement is essential for efficacy and safety endpoints.

Distinguish psychotherapy/facilitation functions from outcome assessment and other research tasks. Separation reduces bias and protects the integrity of blinded assessments.

Ability to monitor for opioid use recurrence, other substance use, and ketamine misuse during the trial. The clinician must recognize relapse risk and take action when substance use worsens.

Facilitators should be able to contain and make therapeutic use of profound emotional or peak experiences, including ego loosening, awe, reassurance, and feelings of unity or peace. The article suggests these experiences can be highly meaningful and therapeutic, but not all need to meet full mystical criteria.

Because the protocol involved specific LSD doses, active placebo control, and session spacing, facilitators need applied skill in implementing dosing-session procedures safely and consistently. This includes maintaining therapeutic support while adhering to protocol constraints.

Therapists should identify or teach in-session coping tools and collaboratively plan how anxiety states will be recognized and supported.

Help patients engage in emotionally intense trauma-focused treatment and reduce dropout risk. The therapist should recognize comorbid depression or anxiety that may interfere with adherence and response.

Teaches the requirement for site personnel to be trained and certified on protocol-specific assessments, psychiatric instruments, rating scales, and study procedures before performing them in the trial.

Therapists must be specifically trained in psilocybin-assisted psychotherapy and in the study’s manualized procedures. Competence includes familiarity with the therapeutic model and difficult-state management guidance.

Therapists need a solid professional background in psychotherapy, especially PTSD treatment. Prior experience with established trauma therapies and related approaches is considered important preparation for this work.

Facilitators need conceptual knowledge of normal grief, prolonged grief disorder, and the rationale for preventive and therapeutic grief care. This informs formulation, pacing, and risk awareness in the protocol.

Therapists must help participants identify, recover, and translate values into concrete behavior change. The manual treats values work as central to depression recovery and integration.

Work within a supervised treatment model that includes review of recorded sessions and feedback. The facilitator must accept supervision, use feedback constructively, and support fidelity reviews.

The handbook explicitly states that the experience should be fully explained and that the subject should accept it voluntarily. Coercion is framed as both unethical and therapeutically counterproductive.

The protocol expects involvement of relatives in follow-up, indicating a facilitator competency in engaging collateral supports. This helps verify outcomes and sustain recovery monitoring.

Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.

Cluster covering 2 related competencies including: Trauma-informed care, Trauma-informed psychedelic care.

Teaches practitioners to identify and apply relevant legal, regulatory, ethical, and institutional requirements, including documentation, consent, reporting, controlled-substance, and jurisdiction-specific obligations.

Learners are explicitly offered Basic Life Support training, indicating emergency readiness and medical safety preparation. The page notes DORA-required status, signaling regulatory safety relevance.

Cluster covering 2 related competencies including: Dosing-day facilitation, Dosing-session facilitation.

Responds to distressing anxious or psychotic reactions with verbal de-escalation and, if needed, rescue medications. Escalates intervention in a stepwise manner based on clinical response.

Track the participant’s subjective drug intensity during the active phase of the session. This includes recognizing when the participant cannot respond and how to document maximum intensity.

Develop follow-up care after the acute ibogaine period to support behavior change and relapse prevention. The manual emphasizes that the treatment session alone is not enough for long-term recovery.

The intervention targets anxiety associated with life-threatening diseases, so therapists need knowledge of the psychological burden of severe medical illness and the clinical presentation of anxiety in this population. They must be able to formulate treatment needs in medically ill patients.

Therapists must remain with participants at the end of and immediately after experimental sessions until emotional stability is established. This requires real-time clinical judgment about readiness for reduced supervision.

The therapist must exercise clinical judgment about who may benefit, who may have difficulty surrendering defenses, and where evidence is limited. The handbook emphasizes uncertainty, need for research, and cautious selection based on insecurity, rigidity, suspicion, diagnosis, and treatment goals.

Ability to contribute to evaluation of the effectiveness of LSD-assisted psychotherapy. The study is explicitly described as investigating safety and effectiveness.

Track onset, duration, and phases of ibogaine effects as part of clinical monitoring. The manual describes multiple stages of effect and expects the provider to observe them carefully.

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

Collect and interpret baseline behavioral, psychiatric, and medical history relevant to psilocybin research. This information is used to determine eligibility and contextualize outcomes.

Use physical contact only when necessary, explicitly permitted, and minimal. The facilitator must respect participant autonomy and avoid any contact that is not justified for safety or grounding.

Therapists must help participants manage disclosure, social support, and media contact carefully to protect privacy and emotional safety. They should advise discretion without controlling the participant's choices.

Work within protocol-defined limits of therapist support. The trial excluded participants whose conditions could jeopardize rapport given those limits, underscoring the need for clear boundaries.

Facilitators require skill in establishing ceremonial and intentional framing around ketamine sessions to support therapeutic depth and coherence. This includes preparing participants for the significance and structure of the experience within the group model.

The investigator/therapist has ethical responsibility to explain study goals, course, expected effects, possible advantages and disadvantages, risks, and alternative treatments in verbal and written form. This includes ensuring participant questions are answered satisfactorily and that there is enough time for decision-making.

Knows the conditions that may disqualify a person from ketamine treatment and can apply that knowledge during screening. Recognizes medical, psychiatric, pregnancy-related, and substance-related contraindications.

Staff must ensure participants can understand and engage with the protocol in the site’s recognized language and can participate in a way that preserves safety and informed consent. This is part of the practical knowledge needed for ethical facilitation.

Responsibility to practice ethically in a psychedelic-assisted therapy research context. Given the use of MDMA in a clinical trial, therapists must prioritize participant welfare, informed participation, and protocol integrity.

The review explicitly discourages clinical development based on toad venom because of ethical and ecological concerns. Facilitators should favor synthetic sources and avoid practices that could harm wildlife or ecosystems.

Ensure that administration occurs within an ethically supervised research or clinical framework with informed oversight and careful risk-benefit consideration. Hallucinogenic agents require especially cautious use in vulnerable psychiatric populations.

Ability to attend closely to participant responses during altered states and validate them without pathologizing normal psychedelic phenomena. This supports safety and meaning-making.

Therapists/facilitators must ensure participants are properly informed using approved consent materials before participation in MDMA-assisted psychotherapy research.

Clearly explain the investigational nature of ibogaine treatment and its known serious risks before treatment begins. Ethical practice requires that patients understand both uncertain benefits and significant safety concerns.

Therapists must work thoughtfully with the patient's social support system to enhance safety and continuity of care. This includes selective disclosure, education, involvement in sessions when appropriate, and crisis planning.

Safe delivery requires coordination among therapists, physicians, nurses, blinded assessors, outside therapists, and emergency services.

Therapists need specific knowledge of methamphetamine use disorder, HIV risk behaviors, and the social context of affected populations to deliver relevant and responsive care. This includes understanding how methamphetamine use intersects with trauma, sexual risk, and HIV prevention or treatment adherence.

The therapist/facilitator should know the expected onset, peak, and persistence of effects to guide monitoring and interpretation. The source reports acute effects with follow-up improvements lasting days.

Review laboratory and biomarker data for clinically significant abnormalities, including chemistry, hematology, coagulation, and alcohol biomarkers. This supports medical safety surveillance during follow-up.

Therapists must provide continuity, availability, and clear support structures after MDMA sessions to reduce anxiety and manage emerging difficulties. This safety net extends beyond the dosing day.

Therapists/facilitators must fulfill professional legal duties and escalate safety or reporting concerns promptly.

Because interviews and questionnaires may provoke emotional reactions or fatigue, facilitators must respond supportively and mitigate burden. This includes addressing distress during assessments and offering breaks.

Therapists in this setting must recognize abnormal cardiovascular responses and follow protocolized responses for hypertensive crisis, angina, myocardial infarction, or stroke.

Recognizes medical factors that may increase risk during inhaled 5-MeO-DMT administration. Medical clearance is required before dosing.

Coordinate the conversion from opioid maintenance treatment to morphine-sulphate prior to ibogaine dosing, reflecting the treatment sequence described in the study. This requires careful timing and clinical oversight.

Ability to observe and interpret defense mechanisms and other psychological processes during therapy. This is implied by the MeSH term 'Defense Mechanisms' and psychotherapy context.

Use music intentionally as part of the therapeutic environment and processing sequence. Music should support, not direct, the patient’s unfolding internal experience.

Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.

Recognize and respond to gastrointestinal adverse effects that may occur frequently with higher doses. Manage emesis to reduce aspiration risk, dehydration, and treatment disruption.

Facilitators must protect participants and others from harm without unnecessarily restraining the participant. The guidance emphasizes containing danger rather than restraining movement.

A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.

Treat consent as a continuing process rather than a one-time event. Patients must understand the treatment and retain the ability to revoke consent, with special procedures during the medication session for safety.

Understands the optional nature and operational limits of biomarker and pharmacogenomic collection. Ensures consent, timing, fasting guidance, and sample handling requirements are respected.

Knowledge of the trial’s primary, secondary, and exploratory endpoints and the instruments used to assess them. This enables accurate administration and interpretation of study procedures.

Facilitators are expected to monitor for signs of misuse, diversion, dependence, or other abuse-related phenomena even though the medication is administered only on-site. They must also recognize protocol violations or dropout patterns that may signal abuse liability concerns.

Maintains awareness that any clinical trial context may involve participant risk and requires appropriate safeguards. Even minimal source text implies the need for cautious, non-assumptive practice.

Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

Understand ibogaine, noribogaine, and noribogaine glucuronide disposition and how exposure relates to clinical effects. This knowledge supports safe interpretation of observed toxicity and response.

Can determine whether a study record actually specifies therapist/facilitator responsibilities or competencies. This includes distinguishing direct treatment skills from administrative registry instructions.

Conduct or support psychiatric screening using clinical interviews and structured diagnostic tools. The goal is to establish baseline mental health status and detect exclusionary disorders or instability.

Identify and document possible post-dose reactivation or flashback-like experiences. The therapist must capture timing, context, emotional valence, and functional impact of these events.

Facilitators need knowledge of conditions and medications that may make 5-MeO-DMT unsafe or inappropriate. They should identify possible interactions and discuss them clearly before participation.

Facilitators should understand that treatment aims include symptom reduction and improved functioning. Support work should attend to both emotional processing and real-world disability.

Facilitators should refer participants to qualified professionals when their needs exceed available support. This is part of responsible care and boundary awareness.

Able to function within an inpatient rehabilitation setting for substance-related disorders. The facilitator must support the structured residential environment and care of patients with addiction comorbidity.

Facilitators must watch for slowed breathing, sleep apnea-related hypoxia, disordered breathing, and oxygen desaturation. Oxygenation needs ongoing assessment during the acute and post-acute periods.

Given the risk of high attrition, facilitators need strong engagement and follow-up skills. The protocol explicitly notes the importance of respecting time commitments, tracking procedures, and strong interpersonal skills of study personnel.

Balances potential symptom relief against known and emerging safety risks in participants with opioid dependence. Makes conservative decisions when cardiac or adverse-effect concerns outweigh anticipated benefit.

Clinical investigators must work within independent safety monitoring structures and avoid conflicts in oversight roles. Therapists/facilitators in research settings should support scheduled review of participant safety outcomes.

Carry out baseline medical safety checks prior to intervention initiation. These assessments reduce risk and support participant suitability.

Recognize when post-session exhaustion or discomfort may warrant supportive symptom management and understand the limited use of sedatives in the protocol. The facilitator must balance comfort with safety and document any sedating agents used.

Collaborates with patients, medical practitioners, and referring providers to support individualized care. Helps patients consider alternatives and coordinate ongoing treatment needs.

The facilitator should be able to manage a brief but intense treatment window. The source suggests a shorter-acting psychedelic may enable rapid onset of response and reduce burden compared with longer-acting agents.

Therapists must assess the participant’s social support network and help plan appropriate use of supportive relationships during treatment. They should guide participants about the potential benefits and risks of sharing their experiences with others.

Ability to facilitate long-duration psychotherapy sessions in a controlled research setting. The study used two 8-hour psychotherapy sessions, requiring sustained therapeutic presence and session management.

Use Subjective Units of Distress Scale ratings to track fear activation and extinction during PE sessions. This requires eliciting reliable distress ratings and using them to guide exposure processing.

Therapists should understand multiplicity of the psyche as a normal phenomenon that may become more apparent in trauma treatment and altered states. They must respond with curiosity and support rather than pathologizing parts, selves, or dissociative phenomena unless clinically necessary.

Because cognitive performance during treatment is a named secondary outcome, clinicians involved in care should be able to monitor and document cognitive functioning relevant to treatment participation. This supports safety oversight and interpretation of treatment effects.

Operate only within the bounds of formal training, supervision, and site authorization. The protocol expects specialized training for facilitators, raters, and all staff interacting with participants or data.

The therapist should assess both the immediate experience and longer-term change, using structured observation, self-report, and reports from others where possible. The handbook treats evaluation as difficult but necessary for understanding therapeutic effects.

Therapists/facilitators should know the main assessment domains used in KPT research and clinical monitoring, including craving, depression, anxiety, anhedonia, addiction severity, and purpose in life. This knowledge supports case formulation and tracking change.

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.

Psilocybin sessions are conducted with two trained therapists, and therapists-in-training may support sessions under supervision. Effective dyad work and supervised learning are central to the model.

LSD-assisted psychotherapy in this study is explicitly framed as medically supervised. Therapists/facilitators need to practice within a setting capable of medical oversight and management of prolonged altered states.

Teaches how to interpret the psychedelic clinical evidence base, compare strength of evidence across indications, understand mechanism theories, and critically appraise research claims. The competency supports evidence-informed practice rather than relying on general field narratives.

Cluster covering 2 related competencies including: Preparation and therapeutic alliance, Preparation and therapeutic alliance building.

Cluster covering 2 related competencies including: Psychedelic harm reduction and integration therapy, Psychedelic harm reduction and integration fundamentals.

Cluster covering 2 related competencies including: Trauma-informed practice, Trauma-informed clinical practice.

Therapists are expected to use concrete active listening skills that support exploration without overdirecting. These communication skills help maintain emotional safety and participant agency.

Ensure required abstinence conditions are met before dosing and make clinical judgments about rescheduling or exclusion when they are not. This protects safety and protocol integrity.

Clinicians must recognize the life-threatening nature of alcohol withdrawal and ensure adequate detoxification before treatment. Postponement and medical supervision are required when withdrawal risk is present.

Therapists should evaluate the participant’s support network and help plan how supports can assist between sessions. They must also guide participants about the benefits and risks of disclosing their experiences to others.

Competent delivery includes monitoring psychosocial functioning in addition to depressive symptoms. The source reports psychosocial functioning as a treatment outcome sustained through follow-up.

Administer study assessments in the correct order and in the correct format. The protocol depends on reliable, standardized administration by trained site personnel and central raters.

Administer and interpret the study's psychosocial measures relevant to existential distress, depression, spiritual well-being, and death-related distress. These assessments are used for screening and outcome monitoring.

Before administration, facilitators should assess readiness and factors that could increase the chance of a difficult session. The source highlights that preoccupation, rigidity, low trust, and poor support can worsen experiences.

Therapists and study staff must manage participant distress and fatigue associated with questionnaires and interviews. Competence includes pacing, offering breaks, and responding supportively to emotionally evocative content.

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

The therapist/facilitator must understand potential drug-interaction concerns and formulation-related differences that could alter tolerability or safety. The source mentions caution with antiemetics and alternative preparations.

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

Evaluate whether a person is an appropriate candidate for ibogaine treatment by balancing potential benefit against medical risk. This includes identifying treatment-refractory opioid use disorder and weighing cardiotoxicity and other safety concerns against the harms of untreated substance use disorder.

Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

The study specifically reports no QT prolongation, indicating that cardiac safety was an important monitoring domain. Facilitators must be aware of relevant safety surveillance and the need to identify concerning effects.

Performs repeated blood pressure screening and interprets values against protocol thresholds before allowing dosing. This includes recognizing measurement artifact and repeating readings when needed.

Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

Clinicians must have working expertise in evidence-based CBT for depression and related mood conditions, including the ability to deliver core CBT components across preparation, post-session integration, and relapse prevention phases. The protocol assumes competence in standard CBT delivery as the psychosocial backbone of treatment.

Some listed programs explicitly teach clinical documentation and related practice management skills. This suggests learners may be expected to document care, coordinate treatment processes, and work within structured clinical workflows.

Assistant facilitators require practical clinical experience in a licensed healthcare setting. Their role supports safety, containment, and session logistics rather than independent psychotherapy practice.

Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.

At least one therapist in the dyad must be a clinician with capability to assess and manage medical or psychiatric adverse events during the dosing session. This reflects a required competency boundary between general support and clinical responsibility.

Deliver structured CBT-based smoking cessation support throughout the trial. Facilitators teach practical self-management strategies before and after the target quit date.

Ketamine-assisted treatment in this protocol is multidisciplinary, so facilitators must work closely with study doctors and nurses. This includes coordinating preparation, understanding monitoring responsibilities, and escalating concerns appropriately.

Facilitators must know that combining 5-MeO-DMT with other psychoactives or MAO-inhibitors can be dangerous or fatal. Careful pacing and separation from other substances are necessary.

Responsible practitioners cultivate relationships with other practitioners and community networks to support sustainable care. They help build systems that expand access while preserving integrity and safety.

Understand the transition from blinded randomized treatment to open-label MDMA-assisted therapy for eligible participants. This includes separate consent, revised scheduling, and altered assessment timing.

Facilitators may use ritual, music, prayer, altar work, or minimalist approaches to frame the experience. Whatever the style, they should use contextualization intentionally and in service of the participant’s process.

Participants must be continuously monitored to prevent avoidable hazards. The guide explicitly states that participants should never be left alone.

Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.

Facilitators should know when and how to ask for help and delegate tasks. This is essential in emergencies and difficult situations.

Trainers and mentors observe therapists for conduct that could place participants at risk. Therapists must be receptive to correction and able to modify problematic behavior or seek additional training.

Ability to judge clinical worsening over time and determine whether a participant can remain in the study or requires higher-level care. This is a continuing monitoring responsibility throughout the trial.

Identifies and reports device deficiencies and product quality complaints related to the nasal spray device or product packaging. Ensures immediate escalation when malfunctions or labeling issues occur.

The therapist/facilitator must record participant-reported effects and clinically relevant observations accurately. Documentation supports both safety monitoring and outcome interpretation.

Knowledge of anorexia nervosa symptomatology, risk, and clinical instability relevant to screening and treatment monitoring. The study requires awareness of eating-disorder-specific risks and outcomes.

Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.

Knows the purpose and indications of medications maintained for side effect management or emergency use during KAP. Can explain how these medications relate to specific risks.

A clear emergency plan is required before the session begins. The whole team must understand what to do in various scenarios.

Be prepared to recognize medical deterioration and summon emergency help immediately. The manual states that providers who cannot call for emergency assistance should not provide ibogaine therapy.

Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.

Communicates the experimental and unregulated nature of ibogaine treatment honestly. The source highlights an ibogaine subculture offering unregulated preparations, which creates an ethical duty to disclose uncertainty and risks.

Uses a cautious, transparent ethical approach when working with an experimental or non-approved addiction treatment context.

Provide reassurance when it helps establish safety, while avoiding invalidation or minimization. Reassurance should support rather than dismiss the patient’s experience.

Interprets mescaline responses in light of the study population and design. Understands that findings from healthy subjects may not directly generalize to clinical populations or unsupervised use.

Therapists/facilitators should be able to educate companions about clinical warning signs and how to contact the study team. This extends monitoring beyond the clinic and supports rapid response to deterioration.

Responds appropriately to safety threats disclosed in group therapy. Follows up on suicide, homicide, abuse, or neglect concerns and escalates when necessary.

Providers must maintain hydration and avoid electrolyte depletion because dehydration and electrolyte abnormalities increase cardiac risk. Hydration is to be monitored before, during, and after treatment.

Prevent dehydration during and after ibogaine treatment. The manual stresses that patients may not feel like drinking and that dehydration can become dangerous, especially if vomiting occurs.

Understand the unique cardiovascular hazards associated with ibogaine and the need for intensive cardiac oversight. The facilitator should know that cardiac risk is a central safety issue rather than a minor side effect.

The study examines whether early improvement during PE relates to dropout rates, implying a competency in recognizing early response patterns and engagement risk. Therapists should monitor participation closely and intervene to support retention when possible.

Understands the implications of PET, MRI, blood sampling, and TMS-EEG procedures for participant comfort and safety. While not necessarily performing these procedures, the therapist/facilitator should know their risks and scheduling constraints.

Therapist/facilitator practice in the study must align with equity, diversity, and inclusion commitments by avoiding exclusions based on protected or social identity characteristics outside protocol-defined scientific/safety criteria. This supports ethically sound participant engagement.

Investigators have a continuing duty to inform participants about new findings regarding LSD or LSD-assisted therapy that emerge during the study. This reflects an ongoing consent responsibility rather than a one-time disclosure.

Use ibogaine only after a careful discussion of uncertain efficacy, limited research, and known risks. Ethical practice requires transparent communication about the experimental nature of treatment and the absence of robust clinical standards.

Study personnel involved with participants must understand informed consent responsibilities and boundaries. Consent is an ongoing process, and appropriately trained staff without an existing clinical relationship obtain consent, not the PI.

Exercises heightened ethical responsibility when working with people with opioid dependence undergoing medication changes. Ensures participation remains voluntary, monitored, and clinically appropriate.

Facilitators should understand the therapeutic and adverse-effect context of psilocybin and comparator antidepressant treatment, since the trial directly compared psilocybin with escitalopram.

Clinicians need working knowledge of the potential risks and benefits of MDMA-assisted therapy as the research is designed to explore both. This knowledge supports informed consent, clinical judgment, and participant monitoring.

Collect biological samples and interpret their role in safety and exploratory analyses. Facilitators need procedural competence in sample handling and visit timing.

Order, review, and interpret core laboratory studies relevant to ibogaine safety and metabolism. Competence includes recognizing abnormal values that increase risk or signal exclusion from treatment.

Those organizing sessions should understand the legal implications of ayahuasca in their jurisdiction. This helps them manage accountability and reduce legal risk.

Explains the boundaries of confidentiality so patients understand when information may be disclosed without permission. Applies legal and ethical duties related to safety, abuse, and mandated reporting.

The facilitator must make repeated documented efforts to contact participants who miss visits. Follow-up processes differ for responders and non-responders.

Providers must be able to recognize and safely manage acute confusional states, which may look like a psychological break from reality. The emphasis is on physical safety, constant supervision, and avoiding abrupt antipsychotic intervention.

Facilitators need competence in working with PTSD when comorbid conditions are present. The source explicitly notes dissociation, depression, alcohol/substance use disorders, and childhood trauma.

Plans and maintains support for sessions that may last many hours. Duration of effects can be substantial and requires sustained facilitator availability and structured observation.

Respond promptly to complications arising during ibogaine-supported detoxification. Facilitators need a clear escalation plan for QTc prolongation and intolerable withdrawal.

5-MeO-DMT produces a very short but intense experience, which changes facilitation demands. Facilitators must be prepared for rapid transitions into and out of the altered state.

Therapists/facilitators must monitor for adverse medical signs during sessions and obtain targeted testing when clinically indicated. Safety practice should balance participant comfort with symptom-triggered medical evaluation.

Screen for co-medications that may prolong QTc or affect CYP2D6 metabolism. This is critical to reduce confounding and prevent additive toxicity.

Therapists must understand clinically significant drug interactions with ibogaine, including QT-prolonging, serotonergic, centrally acting, and CYP2D6-related medications. This knowledge informs screening, tapering, and dosing decisions.

Train and support participants in use of the study app for dosing, questionnaires, journaling, and reminders. This includes technology-enabled adherence monitoring.

Use video-based direct observation methods to verify medication intake and prevent dose stacking. This is a core adherence-monitoring function in the protocol.

The protocol includes secondary outcomes for depression and anxiety severity, so clinicians should be able to assess and track these domains alongside PTSD symptoms. This broadens case monitoring and supports comprehensive clinical oversight.

Because study drug delivery uses a vaporization device, staff must be able to recognize, document, and escalate device deficiencies. Device issues may have safety implications even when no patient harm occurs.

The therapist should watch for depression after the experience, particularly when insights are not translated into action. Continued support is presented as a way to reduce this risk and restore constructive orientation.

Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.

Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

Ask about symptoms and adverse effects in a neutral, non-suggestive manner. This reduces bias and improves safety detection in a vulnerable oncology population.

Sequences study procedures correctly to reduce bias and protect participant safety. Particularly prioritizes PROs, clinician ratings, and dosing-day procedures in the required order.

Understands that findings from a pilot evaluation support feasibility and preliminary effectiveness rather than definitive efficacy. The facilitator should interpret outcomes cautiously and support structured data collection.

Identify study-drug overdose and respond according to protocol with urgent sponsor notification and clinical monitoring. The protocol defines overdose as more than the assigned dose for that subject.

Supports structured administration and observation within a clinical trial or supervised research setting. Uses protocol-based timing, assessments, and follow-up consistent with phase I human studies.

Understands the clinical context of switching participants from methadone to morphine before study participation. Appreciates how opioid substitution transitions can affect symptom interpretation and safety monitoring.

Applies cautious patient selection when considering ibogaine for opioid detoxification, particularly for individuals with refractory opioid use disorder.

Understands core pharmacokinetic concepts needed to interpret study findings and guide safety observation. Recognizes dose-linear exposure changes and elimination characteristics relevant to monitoring windows.

Before symptoms begin, the therapist must prevent boredom, over-monitoring for effects, and escalating apprehension. This phase is treated as crucial because the psychological set established here shapes much of what follows.

The therapist/facilitator must ensure medical suitability before ayahuasca administration by checking for conditions that increase risk. Screening should include physical exam, laboratory testing, and pregnancy assessment when indicated.

Therapists must prepare participants psychologically and practically for ketamine dosing through rapport-building, psychoeducation, expectation-setting, and intention development. Preparation is emphasized because of trauma burden, psychiatric comorbidity, and instability in the target population.

Verify the formulation and potency of the ibogaine product before administration. The manual warns that confusion between HCl, extract, and root bark can cause underdosing or fatal overdosing.

Adheres to organizational code of ethics, privacy policy, electronic communication policy, and applicable laws. Maintains professional conduct across contractor and clinic arrangements.

Expectation that study personnel are trained in research ethics and responsible conduct of research. This underpins appropriate consent, confidentiality, and participant safety practices.

Clinicians should present the intervention accurately as ketamine- or midazolam-augmented PE within a research protocol, with clear explanation of purpose and expectations. Ethical practice includes avoiding overstatement of benefit and framing treatment as investigational augmentation of an established therapy.

The facilitator should understand that effects observed in a controlled clinical setting may differ from those in ceremonial or ritual contexts. This awareness shapes interpretation and informs safer translation to other settings.

Because participants may be more suggestible during psychedelic sessions, therapists must actively protect against manipulation and unsafe influence. This requires vigilance and careful conduct.

Help patients navigate craving, relapse risk, and post-treatment vulnerability. The manual notes that fear of relapse is more realistic than fear of withdrawal after ibogaine.

Coordinate with remote central raters for standardized outcome assessment while preserving privacy and safety. The site must ensure the setting is private and that safety concerns are relayed back to the site promptly.

Use rescue medications only after non-medical interventions have failed, and only by the study site-designated physician. Selection must consider local standard of care, subject history, and QTc risk.

Understands that mescaline is a classic serotonergic psychedelic with substantial acute psychoactive effects. Uses this knowledge to prepare for altered perception and prolonged subjective responses.

Can explain common, psychological, and severe risks of KAP in understandable terms. Sets realistic expectations that outcomes may vary and are not guaranteed.

Therapists must monitor a clinically vulnerable population experiencing recent loss and possible PGD risk. The protocol requires special attention to psychological destabilization, distress, and functional impairment.

Understand the rationale and risks of home-based psychedelic microdosing in a naturalistic environment. Facilitators need awareness of adherence, stacking, and behavioral risk considerations.

Facilitators need working knowledge of administration routes because onset, duration, intensity, and tolerability vary substantially. This informs preparation, monitoring, and participant education.

If physical intervention is needed, it must be done carefully to reduce risk such as choking or aspiration. The facilitator should understand safer alternatives and avoid dangerous techniques.

Ability to recognize when a source does not provide enough information to infer clinical safety responsibilities or therapist competencies. This prevents unsupported claims about monitoring or intervention delivery.

Maintain physical, emotional, and relational safety as the primary guiding principle throughout IMAP. Therapists continuously monitor risk, reinforce boundaries, and intervene more directly when safety is compromised.

Recognizes that a study involving a psychoactive compound requires careful attention to participant safety during screening and participation. Even though the source does not detail procedures, a facilitator must anticipate risk-aware monitoring and escalation.

Decide when sedation is appropriate and select agents that have been used safely in the manual’s reports. Sedation is presented as optional and patient-specific, not routine.

Facilitators should understand how to work in one-on-one, group, and advanced simultaneous group formats. They must clearly explain the context, method, and risks of their chosen format.

Clinicians must ensure participants meet day-of-session safety requirements before psilocybin is administered. This includes verifying toxicology, pregnancy, alcohol abstinence, and adherence to protocol restrictions.

The facilitator influences the participant’s mindset through tone, language, responsiveness, and overall presence. They should intentionally support a conducive mental set from first contact through post-session care.

Supports rigorous conduct of randomized controlled safety studies by maintaining protocol adherence and minimizing bias. Protects the validity of safety, tolerability, and exploratory efficacy assessments.

Confirm ongoing eligibility throughout the study and recognize conditions that require withdrawal or reassessment. Eligibility is not static and must be checked before key sessions.

Explain study rules, session expectations, and restrictions clearly to the subject. Education supports adherence, safety, and informed participation.

Protect participant welfare during and after study participation, including ensuring appropriate psychiatric follow-up. The site is responsible for post-study care planning and referral.

Know that ayahuasca composition can vary and that chemical characterization matters. Facilitators or clinical teams should understand the potency and stability of the administered brew.

Ability to support supervised at-home ketamine use when clinically appropriate. This implies monitoring and structure even outside the office setting.

The article indicates that a structured, supportive context is associated with more positive acute and enduring effects and fewer challenging experiences. Facilitators should actively design the session context around safety and support.

Therapists must create and maintain a calm, supportive setting during MDMA administration. The session environment is intended to maximize comfort and facilitate therapeutic work while minimizing risk.

Monitor body temperature during sessions and intervene if it rises beyond expected limits. The protocol specifies active cooling steps and escalation thresholds.

Respect patient autonomy while maintaining safety boundaries during a high-risk intervention. The protocol allowed return to opioid substitution therapy when clinically needed.

Therapists must closely attend to the patient's speech, affect, movement, silence, and bodily signs to understand process and determine appropriate intervention. Fine-grained observation is necessary for both safety and therapeutic timing.

Use a caring, natural, and non-threatening interview style to assess psychiatric and psychological domains. The protocol emphasizes normalization, reduction of guilt, symptom exaggeration techniques, and a logical flow that facilitates rapport.

The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.

Recognize that current evidence does not establish the lowest effective or safest exposure for ibogaine. Facilitators must understand the uncertainty surrounding efficacy at reduced doses.

Facilitators must know the study timeline to conduct therapy and safety checks at the correct times. They should understand which visits are in person, virtual, or questionnaire-only and what assessments occur at each stage.

Facilitators must coordinate appropriate overnight support personnel and ensure they are trained for the role. Attention to participant comfort and boundaries is built into staffing decisions.

Understand the domains assessed in the Storyline psychiatric and neurological interviews and use this knowledge to support accurate administration and interpretation of study tasks. Domains include cognition, mood, homeostasis, social support, and psychosis/suicidality screening.

Therapists should validate positive, affirming, and resourcing experiences as meaningful components of healing, growth, and meaning-making.

Monitor and address nicotine withdrawal symptoms and smoking urges across the treatment window. Facilitators help participants manage discomfort and sustain abstinence through high-risk periods.

Teaches applied competence through role play, case discussion, peer consultation, seminars, mentorship, and learning-community structures. The emphasis is translating theory into practice, receiving feedback, and developing reflective clinical judgment with peers.

Cluster covering 4 related competencies including: Ethical practice, Ethics in psychedelic care, Ethics and ethical practice.

Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.

The page highlights best-in-class clinical training for drug trials and AI-supported evaluation. Learners are expected to refine skills quickly and receive targeted feedback in training or evaluation contexts.

The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.

The practicum explicitly says sites cover ethical considerations such as confidentiality, privacy, professional conduct, and ethical decision-making. Ethical alignment is also part of site approval.

The course repeatedly emphasizes ethical considerations, safety, and integrity in practice. Learners are expected to develop a grounded professional stance that respects legal boundaries and participant welfare.

The course explicitly includes ethical and relational considerations in crisis response. This suggests learners are trained to act with care, boundaries, and attunement when responding to acute distress.

The page includes explicit warnings about what graduates can and cannot legally do. Learners are expected to understand scope limits, licensure requirements, and when consultation supervision is needed.

Trainees receive templates such as consent and intake forms, informational documents, and guidelines, which implies competence in using standardized practice materials. The page also signals procedural support for safe and organized care delivery.

The course explicitly states that facilitators are guided in safety, ethics, and responsibility. Learners are expected to recognize and manage the unique risks of working with altered states.

The practicum requires placements at pre-approved sites and emphasizes legal and ethical standards. Learners are exposed to different settings, including clinical, retreat, and harm reduction organizations.

The program states that the virtual training has been streamlined so students feel safe and supported no matter what arises. This signals competency in maintaining safety in online psychedelic support contexts.

Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.